BSI-201 is a small molecule believed to achieve its anti-neoplastic
effect by covalently binding and inhibiting PARP-1.When given as
a single agent and in combination with other cytotoxic agents,
BSI-201 is active against a broad range of cancer cells in culture,
including drug resistant cell lines.
BiPar Sciences presents interim phase 2 results for PARP inhibitor BSI-
201at San Antonio Breast Cancer Symposium.Cancer Biol Ther. 2009
Jan;8(1):2-3.